Organ-metastatic landscape delineates overall and site-specific immune-related adverse events of PD-L1 blockade in advanced NSCLC - PubMed
5 hours ago
- #NSCLC
- #immune-related adverse events
- #PD-L1 blockade
- Study examines the relationship between organ metastases and immune-related adverse events (irAEs) in advanced NSCLC patients treated with PD-L1 blockade.
- Retrospective analysis of 708 patients from OAK and POPLAR trials shows varying irAE frequencies based on metastasis sites.
- Bone and pleural effusion metastases associated with lower irAE frequency; brain metastasis linked to higher irAE occurrence.
- Site-specific irAEs vary: hepatitis, hypothyroidism, and rash less frequent with bone metastasis; pneumonitis, adrenal insufficiency, and ocular toxicity more common with brain metastasis.
- Developed a metastasis-based scoring system to identify high-risk populations for irAEs in NSCLC patients receiving PD-L1 blockade.
- Findings suggest organ-metastatic landscape can predict irAEs in advanced NSCLC patients undergoing PD-L1 blockade therapy.